{
  "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
  "Country": "DE",
  "PICOs": [
    {
      "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "Docetaxel (only for patients with PD-L1 negative tumours)",
      "Outcomes": "overall survival, progression-free survival, symptomatology, health status"
    },
    {
      "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "Pemetrexed (only for patients with PD-L1 negative tumours and except in cases predominantly squamous histology)",
      "Outcomes": "overall survival, progression-free survival, symptomatology, health status"
    },
    {
      "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "Nivolumab",
      "Outcomes": "overall survival, progression-free survival, symptomatology, health status"
    },
    {
      "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "Pembrolizumab (only for patients with PD-L1 expressing tumours (PD-L1 expr â‰¥ 1% of tumour cells))",
      "Outcomes": "overall survival, progression-free survival, symptomatology, health status"
    },
    {
      "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "Atezolizumab",
      "Outcomes": "overall survival, progression-free survival, symptomatology, health status"
    },
    {
      "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "Docetaxel in combination with nintedanib (only for patients with PD-L1 negative tumours and adenocarcinoma histology)",
      "Outcomes": "overall survival, progression-free survival, symptomatology, health status"
    },
    {
      "Population": "Adults for whom docetaxel is the appropriate patient-individual therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "Docetaxel",
      "Outcomes": "overall survival, morbidity, health-related quality of life, side effects"
    },
    {
      "Population": "Adults for whom a therapy other than docetaxel is the appropriate patient-individual therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "Docetaxel",
      "Outcomes": "overall survival, morbidity, health-related quality of life, side effects"
    }
  ],
  "ChunksUsed": 30,
  "ContextTokens": 6930
}